Matching-Adjusted Indirect Comparison of the Efficacy of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis Beyond Week 16
Main Article Content
Keywords
atopic dermatitis, tralokinumab
Abstract
Introduction: Tralokinumab and dupilumab are both licensed for the treatment of moderate-to-severe AD. However, to date no head-to-head studies or indirect comparisons of their efficacy beyond week 16 have been conducted.
Objective: To conduct a matching-adjusted indirect comparison (MAIC) comparing the efficacy of tralokinumab and dupilumab beyond week 16, both used in combination with topical corticosteroids.
Methods: An unanchored MAIC was conducted using individual patient data (IPD) from the ECZTRA 3 tralokinumab trial and aggregate data from the LIBERTY AD CHRONOS dupilumab trial. IPD were selected by applying the inclusion criteria from the LIBERTY AD CHRONOS trial, then weighted to match summary baseline characteristics – age, sex, race, BMI, disease duration, EASI, DLQI, IGA and SCORAD– of patients treated with dupilumab. Tralokinumab efficacy outcomes at week 32 were compared with dupilumab data at week 32 (EASI and IGA only) and week 52.
Results: Baseline characteristics of the matched tralokinumab arm were well balanced with the dupilumab arm. Tralokinumab and dupilumab showed comparable efficacy across all endpoints. The matched proportions of patients achieving IGA 0/1 were larger for tralokinumab patients at week 32 (49.9%) compared with dupilumab patients at week 32 (39.3%) and week 52 (36.0%). The matched differences in IGA 0/1 at weeks 32 and 52 were 10.6% (95% CI: −2.9%, 24.0%; p = 0.12) and 13.9% (95% CI: 0.6%, 27.3%; p = 0.04), respectively. For EASI 75, the proportion of responders was equivalent for tralokinumab and dupilumab (both 71.9%) at week 32 (difference 0%; 95% CI: −12.2%, 12.3%; p = 1.00). The proportion of EASI 75 responders was numerically lower for dupilumab (65.2%) at week 52 compared with tralokinumab at week 32, giving a difference of 6.8% (95% CI: −5.9%, 19.5%; p = 0.3).
Conclusion: These results confirm broadly similar efficacy for tralokinumab and dupilumab beyond week 16.
References
2. Tralokinumab SmPC.
3. Dupilumab SmPC.
4. Phillippo DM et al. Med Decis Making 2018;38:200–211.
5. Silverberg JI et al. Br J Dermatol 2021;184:450–463.
6. Blauvelt A et al. Lancet 2017;389:2287–2303.
7. Signorovitch JE et al. Value Health 2012;15:940–7.
8. Signorovitch JE et al. Pharmacoeconomics 2010;28:935–45.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.